10-K: Nautilus Biotech Reports 2025 Losses, Advances Proteomics Platform

Nautilus Biotechnology, a development-stage life sciences company, reported a net loss of $59.0 million for 2025 as it continues to invest heavily in its Nautilus Voyager™ proteomics platform, targeting a phased commercial launch in late 2026.

Summary

• The company is a development-stage life sciences company with no revenue generated to date, focused on creating the Nautilus Voyager™ platform for proteomics.
• A net loss of $59.0 million was incurred for the year ended December 31, 2025, an improvement from a $70.8 million net loss in 2024.
• The accumulated deficit as of December 31, 2025, stands at $332.0 million.
• Cash, cash equivalents, and short-term investments totaled $103.4 million as of December 31, 2025.
• Management believes existing cash, cash equivalents, and short-term investments will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months.
• Research and development expenses decreased by $9.4 million, or 19%, to $41.1 million in 2025, driven by operating efficiencies, lower development-related costs, and workforce reductions.
• General and administrative expenses decreased by $5.3 million, or 17%, to $25.7 million in 2025, primarily due to lower stock-based compensation and professional services fees.
• The Iterative Mapping Early Access Program was launched in January 2026, starting with the Tau Proteoforms assay.
• Commercial launch for pre-orders of the Nautilus Voyager™ platform is expected in late 2026, with instrument installations at customer sites anticipated to begin in early 2027.
• General availability of Broadscale proteomics capabilities is expected in the first half of 2027.
• The company's common stock transferred its listing to the Nasdaq Capital Market on October 29, 2025, and regained compliance with Nasdaq's minimum bid price requirement on November 3, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, high-reward scenario. While the company is making scientific progress and managing some costs, its pre-revenue status, substantial accumulated deficit, and explicit need for future capital raise indicate significant financial challenges and execution risk.

Positives

• Net loss decreased to $59.0 million in 2025 from $70.8 million in 2024, indicating an improvement in financial performance.
• Research and development expenses decreased by 19% ($9.4 million) in 2025, reflecting operating efficiencies and cost optimization efforts.
• General and administrative expenses decreased by 17% ($5.3 million) in 2025, primarily due to reduced stock-based compensation and professional services fees.
• The Iterative Mapping Early Access Program was successfully launched in January 2026, providing initial customer access to the platform.
• Strategic research collaborations have been established with leading institutions like Genentech, The Buck Institute for Research on Aging, The Michael J. Fox Foundation, Weill Cornell Medicine-Qatar, and the Allen Institute.
• The company regained compliance with Nasdaq's minimum bid price requirement on November 3, 2025, stabilizing its listing status.
• The Nautilus Voyager™ platform is designed to offer differentiated proteomics technology with extreme sensitivity, broad proteome profiling, proteoform-level depth, and high reproducibility, addressing key limitations of existing technologies.
• The platform's design for immense data production capacity coupled with machine learning is expected to deliver results easily integrated into multi-omics for rapid insight generation and continuous improvement.

Negatives

• The company is a development-stage entity with no revenue generated to date and has incurred net losses in every period since inception.
• An accumulated deficit of $332.0 million as of December 31, 2025, highlights significant historical losses.
• Cash, cash equivalents, and investments decreased from $206.1 million in 2024 to $156.1 million in 2025, indicating a substantial cash burn rate.
• Interest income decreased by 27% in 2025 due to lower cash balances and decreased yield rates on investments.
• The company expects to incur substantial losses and negative cash flows for the foreseeable future and will require significant additional capital.
• A workforce reduction was implemented in the first quarter of 2025, which could potentially impact employee morale and future talent acquisition.
• The common stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market, which can be perceived as a downgrade in listing quality.
• The company previously received a deficiency notice from Nasdaq for not meeting the minimum bid price requirement, indicating past stock price volatility and ongoing listing risks.

Risks

• The business is entirely dependent on the successful development and commercialization of the Nautilus Voyager™ platform, which remains in the development stage and is subject to scientific and technical validation, delays, technical challenges, and market acceptance challenges.
• The company may not compete successfully with its initial or future products in the highly competitive life sciences technology market.
• Dependence on third parties for certain aspects of the development and commercialization of the Nautilus Voyager platform, with potential for delays or failure to meet specifications.
• The business depends significantly on research and development spending by pharmaceutical companies, academic institutions, and other research institutions, and any reduction in spending could limit demand for products.
• There is a risk of material delays in the commercialization program relative to current expectations, or failure to launch successfully.
• Operating results may fluctuate significantly in the future, making them difficult to predict and potentially causing them to fall below expectations.
• The company expects to need to raise additional capital to fund development and commercialization plans, which may not be available on favorable terms or at all, potentially leading to dilution or restrictive debt covenants.
• Inability to obtain and maintain sufficient intellectual property protection for products and technology, or if the scope is not broad enough, competitors could develop similar products.
• Potential involvement in litigation to enforce or defend intellectual property rights, or to defend against claims of infringement, which could be expensive, time-consuming, and unsuccessful.
• Products could have unknown defects or errors, which may give rise to claims and adversely affect market adoption.
• Products may become subject to regulation by the FDA or other regulatory authorities in the future, even if not currently intended for diagnostic use, leading to significant time and expense for approvals.
• Subject to U.S. federal and state laws and regulations, as well as international laws, relating to the collection, storage, and processing of personal information, with potential for non-compliance and harm to business.
• Increased risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws if international development and commercialization activities expand.
• Environmental and health safety laws, including any failure to comply, may result in liabilities, expenses, and restrictions on operations due to the use of hazardous materials and high-powered laser systems.
• Employees, independent contractors, consultants, commercial partners, distributors, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards.
• Significant disruption in information technology systems or breaches of data security could adversely affect the business.
• Inability to manage anticipated growth effectively, placing significant strains on management, operational, and manufacturing systems.
• High dependence on key personnel; inability to recruit and retain them could hinder goal achievement.
• Unfavorable U.S. or global economic conditions, geopolitical conflicts, changing tariffs, and financial market instability could adversely affect the ability to raise capital and business operations.
• Global supply chain interruptions may negatively impact the development and commercialization of products.
• The market price of common stock has been and may continue to be volatile, which could result in substantial losses for investors.
• The company does not expect to pay any dividends for the foreseeable future, meaning investors must rely on stock price appreciation for returns.
• Bylaws designate a state or federal court within Delaware as the exclusive forum for substantially all disputes, potentially limiting stockholders' choice of forum.
• Delaware law and corporate provisions might discourage, delay, or prevent a change in control or management.
• Increased costs and management resources due to operating as a public company.
• Reports published by analysts, including projections differing from actual results, could adversely affect the price and trading volume of common shares.
• Increased scrutiny of environmental, social, or governance (ESG) responsibilities may result in additional costs and risks, and may adversely impact reputation.

Future Outlook

The company expects to incur substantial losses and negative cash flows for the foreseeable future as it continues to invest heavily in the research, development, and planned commercialization of its Nautilus Voyager™ platform. Commercial launch for pre-orders is anticipated in late 2026, with instrument installations beginning in early 2027, and general availability of Broadscale proteomics capabilities expected in the first half of 2027. The company plans to continuously expand platform capabilities, build scalable manufacturing, and develop a long-term platform ecosystem, with an eventual expansion into adjacent and future markets like drug discovery and clinical diagnostics. Substantial additional funding will be required to support these future operations.

Management Comments

• Sujal Patel, President and CEO, certified that the Annual Report on Form 10-K does not contain any untrue statement of a material fact or omit material facts, and that financial statements fairly present financial condition, results of operations, and cash flows.
• Anna Mowry, Chief Financial Officer, certified that the Annual Report on Form 10-K does not contain any untrue statement of a material fact or omit material facts, and that financial statements fairly present financial condition, results of operations, and cash flows.
• Management believes the proteome represents one of the largest and least characterized areas of opportunity in modern biology and medicine.
• Management believes incremental improvements to existing technologies are insufficient to overcome current limitations, and a fundamentally new measurement paradigm (Iterative Mapping) is required.
• Management anticipates the Nautilus Voyager platform will generate the large volumes of high-quality data needed to train AI models of biology.
• Management believes the Nautilus Voyager platform has the potential to be uniquely positioned in the proteomics market and facilitate a broader transformation across life sciences and healthcare.
• Management views the core design thesis behind Iterative Mapping technology development as a non-traditional approach requiring thinking at the intersection of life sciences, computer and data sciences, and physical sciences and engineering.
• Management believes the Nautilus Voyager platform's sensitivity, targeting detection of events as rare as 1 protein molecule in 1,000 cells, will be critically important for biomarker discovery.
• Management believes the study of proteoform patterns, frequency, and diversity of drug targets will be a widely used application of the Nautilus Voyager platform.
• Management believes the Nautilus Voyager platform design is ideally suited for the quality, stability, and speed required to fully realize the value of accessing deep proteomic profiling data to identify biomarkers that stratify patients for clinical trials and improve drug development.

Industry Context

StockSavvy.ai notes that Nautilus Biotechnology operates in the highly competitive and rapidly evolving life sciences technology market, specifically proteomics. The company aims to disrupt a market currently dominated by mass spectrometry-based and affinity-based technologies, which are projected to grow to approximately $57 billion by 2030 (13% CAGR). The emphasis on single-molecule analysis, proteoform-level depth, and AI integration positions Nautilus to address long-standing limitations in comprehensive proteome characterization, a critical need given that proteins drive cellular function and disease, and account for 95% of FDA drug targets. The industry is seeking breakthroughs beyond genomics and transcriptomics to unlock deeper biological insights, and Nautilus's approach could significantly impact drug discovery, biomarker development, and precision medicine if successfully commercialized.

Comparison to Industry Standards

• The Nautilus Voyager™ platform aims to decode and quantify approximately 95% of the entire proteome, including proteoforms, which significantly surpasses the routine detection capabilities of existing mass spectrometry-based methods (approximately 8% from blood and 30% from cells).
• Unlike current affinity-based approaches that are constrained by reagent availability and performance, Nautilus's Iterative Mapping is designed to provide proteoform-level depth and high reproducibility, addressing a key limitation in the industry.
• The Nautilus Voyager™ platform is designed to achieve industry-leading reproducibility across instruments, users, and labs, aiming to overcome the discordance often found in data generated by existing proteomics technologies.
• The company expects its instrument price point to be comparable to high-end mass spectrometry platforms, targeting an existing installed base of over 16,000 mass spectrometry instruments, positioning it as a competitive alternative.
• The platform's single-molecule digital counts are designed for easier integration with genomics and transcriptomics data, offering a more complete multi-omic understanding compared to traditional proteomics data.
• Nautilus believes its platform will generate the massive, high-quality datasets required to effectively train AI models of biology, a capability that existing proteomics technologies struggle to provide at the necessary scale and quality.

Corporate Governance

Legal Proceedings

• On December 14, 2023, the company filed a lawsuit in the U.S. District Court for the Northern District of California against Somalogic, Inc. (now part of Standard Biotools, Inc.) and the California Institute of Technology, seeking declaratory judgment of non-infringement of US Patent No. 7,842,793 related to DNA origami structures.
• On November 19, 2024, the company, Standard Biotools, Inc., and the California Institute of Technology agreed to dismiss the suit and settle all related disputes and claims.

Stakeholder Impact

• Shareholders face potential dilution from future equity capital raises and rely solely on stock price appreciation for returns, as no dividends are expected. The stock price has been volatile, and the transfer to Nasdaq Capital Market indicates ongoing market challenges.
• Employees experienced workforce reductions in Q1 2025, which could affect morale and future recruitment. The value of stock options as incentives may be impacted by stock price fluctuations.
• Customers stand to benefit from the potential of the Nautilus Voyager™ platform to provide comprehensive, reproducible, and scalable proteomic data, initially through fee-for-service offerings and later through instrument sales.
• Suppliers and partners are critical to the company's development and manufacturing, with a reliance on single-source suppliers for certain components posing supply chain risks. Collaborations are key for scientific validation and application development.
• Creditors may face restrictions on the company's operations if future debt financing imposes additional covenants.

Next Steps

• Continue advancing the development of the Nautilus Voyager™ platform across chemistries, reagents, consumables, instrumentation, and analysis software.
• Optimize flow cell designs, landing pad spacing, density, manufacturing process, and chemistries for commercial flow cells.
• Complete final engineering design of the Nautilus Voyager instrument, integrating high-speed optical subsystem, fluorophore excitation laser, and micro-fluidics system.
• Expand the number of affinity reagent probes and chemistries for both broadscale proteomics quantification and targeted proteoform quantification.
• Continue development of analysis software, with expected improvements to algorithms for speed, accuracy, and reliability.
• Broaden engagement, generate reference datasets, refine workflows, and build commercial momentum through the Iterative Mapping Early Access Program.
• Initiate commercial launch for pre-orders of the Nautilus Voyager™ platform in late 2026.
• Begin instrument installations at customer sites in early 2027.
• Achieve general availability of Broadscale proteomics capabilities in the first half of 2027.
• Expand into adjacent pharmaceutical areas such as drug discovery, translational research, clinical research, trial design, and diagnostics.
• Build out a world-class commercial organization, including sales, marketing, distribution, service, and support capabilities, initially in North America, then Europe, the United Kingdom, and potentially Asia-Pacific.
• Continue investing in internal and external research efforts to accelerate high-quality scientific output and peer-reviewed publications.

Key Dates

Recommendation

StockSavvy.ai recommends a 'Hold' for Nautilus Biotechnology. While the company is developing a potentially disruptive proteomics platform with significant long-term market opportunity and has shown some cost efficiencies, it remains a pre-revenue, development-stage entity with substantial accumulated losses and a stated need for future capital raises. The successful execution of its phased commercialization strategy and securing additional financing are critical, high-risk factors that seasoned investors will monitor closely before committing further capital.

Keywords

Proteomics, Life Sciences, Biotechnology, Nautilus Voyager Platform, Iterative Mapping, Single-molecule analysis, Proteoforms, Drug Discovery, Biomarker Development, Precision Medicine, AI in Biology, SEC Filing, 10-K, Financial Report, Research and Development, Commercialization, Nasdaq